Blood Biomarker vs Tau PET for Treatment Monitoring

V2, Crosslink

🧫

Blood Biomarker vs Tau PET for Treatment Monitoring

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-blood-bi

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Blood Biomarker vs Tau PET for Treatment Monitoring ## Background and Rationale # Blood Biomarker vs Tau PET for Treatment Monitoring Amyotrophic lateral sclerosis (ALS) represents a rapidly progressive neurodegenerative disorder characterized by selective loss of motor neurons, leading to paralysis and eventual respiratory failure. While tau pathology has emerged as a potential contributor to neurodegeneration in ALS, current clinical assessment of anti-tau therapeutic efficacy relies heavil

METHODOLOGY NOTES

**Phase 1: Participant Recruitment and Baseline Assessment (Weeks 0-4)** • Recruit 120 participants with mild-to-moderate ALS (ALSFRS-R score 20-40) • Obtain informed consent and collect demographic data • Perform baseline tau PET imaging using [18F]MK-6240 tracer • Collect baseline blood samples (10mL EDTA tubes) for biomarker analysis • Conduct baseline neuropsychological assessment (MMSE, CDR-SB) • Randomize participants 1:1 to active anti-tau therapy vs placebo **Phase 2: Treatment Initiation and Early Monitoring (Weeks 4-12)** • Administer monthly intravenous anti-tau monoclonal antibody (15mg/kg) or placebo • Collect blood samples at weeks 6, 8, 10, and 12 for biomarker monitoring • Measure plasma p-tau217, p-tau181, NfL, and GFAP using Quanterix Simoa platform • Perform safety assessments and adverse event monitoring • Conduct interim neurological evaluations (ALSFRS-R, muscle strength testing) **Phase 3: Mid-Treatment Assessment (Weeks 12-16)** • Perform second tau PET scan a

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.906118Z'}
summary	# Blood Biomarker vs Tau PET for Treatment Monitoring ## Background and Rationale # Blood Biomarker vs Tau PET for Treatment Monitoring Amyotrophic lateral sclerosis (ALS) represents a rapidly progre
entities	{'genes': ['GFAP'], 'diseases': ['ALS']}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Blood Biomarker vs Tau PET for Treatment Monitoring
methodology_notes	Phase 1: Participant Recruitment and Baseline Assessment (Weeks 0-4) • Recruit 120 participants with mild-to-moderate ALS (ALSFRS-R score 20-40) • Obtain informed consent and collect demographic d
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.906123', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

896

Outgoing

475

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Blood Biomarker vs Tau PET for Treatment Monitoring

derives from (16)

supports (5)

💬 Discussion